These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19436659)

  • 1. Results of the ONTARGET and TRANSCEND studies: an update and discussion.
    Fitchett D
    Vasc Health Risk Manag; 2009; 5(1):21-9. PubMed ID: 19436659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial update: focus on the ONTARGET study.
    Fitchett D
    Vasc Health Risk Manag; 2007; 3(6):901-8. PubMed ID: 18200809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
    Yusuf S
    Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
    Unger T
    Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in cardiovascular risk reduction: implications of ONTARGET.
    Guthrie R
    Clin Cornerstone; 2009; 9 Suppl 3():S18-26. PubMed ID: 19409352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ONTARGET/TRANSCEND Trial Programme: baseline data.
    Sleight P
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Renin-angiotensin-aldosterone system inhibition and cardiovascular protection].
    Oğuz A
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 6():4-12. PubMed ID: 20019467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M
    Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are ACE-inhibitors or ARB's still needed for cardiovascular prevention in high risk patients? Insights from profess and transcend.
    Van Mieghem W; Billiouw JM; Brohet C; Dupont AG; Gazagnes MD; Heller F; Krzesinski JM; Missault L; Persu A; Piérard L; Rottiers R; Vanhooren G; Vervaet P; Herman AG
    Acta Clin Belg; 2010; 65(2):107-14. PubMed ID: 20491360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system.
    Cohn JN
    Adv Ther; 2007; 24(6):1290-304. PubMed ID: 18165212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT
    J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death.
    Strauss MH; Hall AS
    Prog Cardiovasc Dis; 2016; 58(5):473-82. PubMed ID: 26586276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
    Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease.
    White CM; Greene L
    J Manag Care Pharm; 2011 Jun; 17(5 Suppl):S1-15. PubMed ID: 21780334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.
    Zimmermann M; Unger T
    Expert Opin Pharmacother; 2004 May; 5(5):1201-8. PubMed ID: 15155118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II and trials of cardiovascular outcomes.
    Sleight P
    Am J Cardiol; 2002 Jan; 89(2A):11A-16A; discussion 16A-17A. PubMed ID: 11835905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.